

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, August 14th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for first quarter of financial year 2027.

NATCO records ₹794.4 Crore consolidated revenue and ₹206.5 Crore of profit after tax for Q1 FY27

- NATCO recorded consolidated total revenue of INR 794.4 Crore for the quarter ended on 30th June 2026, as against INR 1,390.6 Crore for the corresponding quarter last year. Decline is largely attributable to lower Lenalidomide revenue in the current quarter which was partially offset by growth in the base business. The net profit for the period, on a consolidated basis, was INR 206.5 Crore, as against INR 480.3 Crore for the corresponding quarter last year.
- For the quarter, revenue of the associate company, Adcock Ingram Holdings Limited, South Africa was at INR 1,582.8 crores and profit after tax was at INR 242.2 crores. NATCO's share of profit based on the holding as on 30th June 2026 of 35.75% stood at INR 84.3 crores. In July 2026, NATCO acquired additional 13.25% stake in Adcock Ingram Holding Limited taking the total holdings to 49%.
- The Board of Directors have declared an interim dividend of INR 1.5 per equity share of INR 2 each during Q1FY27.

Segmental Revenue Split (INR Crore)

Business Segments	Q1FY27	Q1FY26
Active Pharmaceutical Ingredients (API)	66.7	52.6
Domestic Pharmaceutical Formulations	136.4	107.0
International Formulations (Incl. profit share and subsidiaries)	477.1	1,120.9
Crop Health Sciences (CHS)	40.8	34.7
Other operating and non-operating income	73.4	75.4
Total	794.4	1,390.6